Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating RET Alterations and Oncogenic Signaling Pathway Aberrations

12 Jul 2019

Abstract excerpt

Abstract Purpose: RET is an emerging oncogenic target showing promise in phase I/II clinical trials. An understudied aspect of RET-driven cancers is the extent to which co-occurring genomic alterations exist and how they may impact prognosis or therapeutic response. Experimental Design: Somatic activating RET alterations were identified among 32,989 consecutive patients with metastatic solid tumors tested with a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Genetic factors in colorectal cancer
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31300450
DOI: 10.1158/1078-0432.ccr-18-4049

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating RET Alterations and Oncogenic Signaling Pathway AberrationsPMID 31300450Read ↗

Genomic landscape of 891 RET fusions detected across diverse solid tumor typesSemantic proximity Read ↗

The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNA.Semantic proximity Read ↗

RET Fusion-Positive Lung Adenocarcinoma: Partner-Specific Clinicopathological Characteristics, Co-Mutation Profiles, and Implications for Targeted and Immunotherapy.Semantic proximity Read ↗

Amplification of Wild-Type RET Represents a Novel Molecular Subtype of Several Cancer Types With Clinical Response to Selpercatinib.Semantic proximity Read ↗

Landscape of potentially targetable receptor tyrosine kinase fusions in diverse cancers by DNA-based profilingSemantic proximity Read ↗

Genomic characterization and outcome evaluation of kinome fusions in lung cancer revealed novel druggable fusionsSemantic proximity Read ↗

RET fusions as primary oncogenic drivers and secondary acquired resistance to EGFR tyrosine kinase inhibitors in patients with non-small-cell lung cancer.Semantic proximity Read ↗

Real-World Clinical Performance of a DNA-Based Comprehensive Genomic Profiling Assay for Detecting Targetable Fusions in Nonsquamous NSCLCSemantic proximity Read ↗

A Performance Comparison of Commonly Used Assays to Detect RET FusionsSemantic proximity Read ↗

Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements Across Cancer TypesSemantic proximity Read ↗

Identification of Actionable Fusions as an Anti-EGFR Resistance Mechanism Using a Circulating Tumor DNA AssaySemantic proximity Read ↗

Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non-small cell lung cancer: Analysis of over 8000 cases.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.